Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,728 across all filing types
Latest filing 2015-03-11 AGM Information
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于召开2014年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2014 Annual General Meeting (AGM) of Kunming Pharmaceutical Group Co., Ltd., including details about the meeting date, voting methods, agenda items, and proxy authorization. It does not contain the actual annual report or financial statements but rather the announcement and procedural information related to the AGM. The document length is about 3050 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2015-03-11 Chinese
会计政策变更公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding changes in accounting policies. It details the adoption of revised accounting standards issued by the Ministry of Finance in 2014, the impact of these changes on financial statement line items, and includes opinions from the board of directors, independent directors, and the supervisory board. The document is relatively short (2795 characters) and focuses on policy changes rather than presenting full financial statements or comprehensive financial performance data. It does not contain a full annual report or interim report but rather a formal announcement about accounting policy changes. This fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement about accounting policy changes without full financial statements or detailed financial analysis.
2015-03-11 Chinese
关于使用部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the use of part of idle raised funds for cash management. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange concerning the management and use of raised funds. The document details the amount of funds raised through a non-public stock issuance, the investment projects funded by these raised funds, and the plan to invest idle raised funds in safe, liquid, and principal-guaranteed financial products. It includes board resolutions, supervisory board opinions, and sponsor institution opinions approving the use of idle raised funds for cash management. The document is a formal announcement about the company's financing fund usage and cash management plans, not a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis but focuses on capital management and regulatory compliance related to raised funds. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2015-03-11 Chinese
关于利用闲置自有资金进行保本投资理财业务的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the use of idle self-owned funds for low-risk, principal-guaranteed investment and wealth management business. It includes details about the board's approval, investment purpose, authorized amount, investment types, risk analysis, and opinions from independent directors and the supervisory board. The document is an announcement of a board decision and investment plan rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data. The document length is 2092 characters, which is relatively short and consistent with an announcement. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it relates to the company's financing activities and capital management through investment of idle funds.
2015-03-11 Chinese
2014年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the 2014 annual report summary of Kunming Pharmaceutical Group Co., Ltd. It contains detailed financial data for the year 2014, including total assets, net profit, cash flow, revenue, and expenses. It also includes shareholder information, management discussion and analysis, business segment analysis, asset and liability analysis, investment status, and fundraising usage details. The document is comprehensive and covers the full fiscal year with substantive financial data and analysis. It is not a brief announcement or a certification letter but a full financial report. Therefore, it fits the definition of an Annual Report (10-K). FY 2014
2015-03-11 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It references auditing standards and the responsibility of the company's board and auditors regarding internal control over financial reporting. The document includes an auditor's opinion on the effectiveness of internal control over financial reporting for the fiscal year ending December 31, 2014. It is signed by a certified public accountant and includes details about the accounting firm. The content is focused on the audit of internal controls rather than a full annual report or financial statements. The document length is 2306 characters, which is relatively short but contains substantive audit opinion content. This matches the definition of an Audit Report / Information (AR) which includes standalone audit reports and applied accounting principles, excluding full annual reports. Therefore, the correct classification is AR with high confidence.
2015-03-11 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.